Acumen Pharmaceuticals
Develops sabirnetug, an investigational antibody for early symptomatic Alzheimer’s disease.
$2.92
After-hours close+0.00 (+0.17%)
At close$2.92(−3.80%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.43 | — | — |
| Aug 2026 | −$0.36 | −$0.45 | −25.2% |
| May 2026 | −$0.40 | −$0.33 | +18.1% |
| Mar 2026 | −$0.50 | −$0.41 | +18.0% |
| Nov 2025 | −$0.63 | −$0.44 | +30.2% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jul 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.43 | — | — | — | — | — |
| Aug 11, 2026 | −$0.36 | −$0.45 | −25.2% | — | $92.0K | — |
| May 12, 2026 | −$0.40 | −$0.33 | +18.1% | — | — | — |
| Mar 26, 2026 | −$0.50 | −$0.41 | +18.0% | — | — | — |
| Nov 12, 2025 | −$0.63 | −$0.44 | +30.2% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 26, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 27, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 15, 2022 | ||||||
| May 16, 2022 | ||||||
| Mar 28, 2022 | ||||||
| Nov 15, 2021 | ||||||
| Aug 16, 2021 | ||||||
| Jul 2, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||